Robert C Block1, Ashley Holub2, Amir Abdolahi3, Xin M Tu4, Shaker A Mousa5, Michael N Oda6. 1. Department of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States. Electronic address: robert_block@urmc.rochester.edu. 2. Department of Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States. 3. Department of Acute Care Solutions, Philips Research North America, United States. 4. Division of Biostatistics & Bioinformatics in the Department of Family Medicine and Public Health, University of California School of Medicine, San Diego, CA, United States. 5. Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, United States. 6. Children's Hospital Oakland Research Institute, Oakland, CA, United States.
Abstract
BACKGROUND/SYNOPSIS: Low-dose aspirin is an effective drug for the prevention of cardiovascular disease (CVD) events but individuals with diabetes mellitus can be subject to 'aspirin resistance'. Thus, aspirin's effect in these individuals is controversial. Higher blood levels of seafood-derived omega-3 polyunsaturated fatty acids (ω3) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also have beneficial effects in reducing risk of CVD events but few studies have examined the interaction of plasma EPA and DHA with aspirin ingestion. OBJECTIVE/ PURPOSE: Our study examined the combinatory effects of EPA, DHA, and aspirin ingestion on HDL-cholesterol (HDL-C) and apoA-I exchange (shown to be associated with CVD event risk). METHODS: 30 adults with Type 2 diabetes mellitus ingested aspirin (81mg/day) for 7 consecutive days, EPA+DHA (2.6g/day) for 28 days, then both for 7 days. Plasma was collected at baseline and at 5 subsequent visits including 4h after each aspirin ingestion. Mixed model methods were used to determine HDL-C-concentrations and apoA-I exchange compared to the baseline visit values. LOWESS curves were used for non-linear analyses of outcomes to help discern change patterns, which was followed by piecewise linear functions for formal testing of curvilinear relationships. RESULTS: Significant changes (p < 0.05) compared to baseline in both HDL-C-concentrations and apoA-I exchange were present at different times. After 7 days of aspirin-only ingestion, apoA-I exchange was significantly modified by increasing levels of DHA concentration, with increased apoA-I exchange observed up until log(DHA) of 4.6 and decreased exchange thereafter (p = 0.03). These LOWESS curve effects were not observed for EPA or HDL-C (p > 0.05). Aspirin's effects on apoA-I exchange were the greatest when EPA or DHA concentrations were moderate compared to high or low. Comparison of EPA, DHA, and EPA+DHA LOWESS curves, demonstrated that the majority of the effect is due to DHA. CONCLUSION: Our results strongly suggest that plasma concentrations of EPA and DHA influence aspirin effects on lipid mediators of CVD event risk where their concentrations are most beneficial when moderate, not high or low. These effects on HDL-C cholesterol and apoA-I exchange are novel. Personalized dosing of DHA in those who take aspirin may be a beneficial option for patients with type 2 diabetes mellitus.
BACKGROUND/SYNOPSIS: Low-dose aspirin is an effective drug for the prevention of cardiovascular disease (CVD) events but individuals with diabetes mellitus can be subject to 'aspirin resistance'. Thus, aspirin's effect in these individuals is controversial. Higher blood levels of seafood-derived omega-3 polyunsaturated fatty acids (ω3) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also have beneficial effects in reducing risk of CVD events but few studies have examined the interaction of plasma EPA and DHA with aspirin ingestion. OBJECTIVE/ PURPOSE: Our study examined the combinatory effects of EPA, DHA, and aspirin ingestion on HDL-cholesterol (HDL-C) and apoA-I exchange (shown to be associated with CVD event risk). METHODS: 30 adults with Type 2 diabetes mellitus ingested aspirin (81mg/day) for 7 consecutive days, EPA+DHA (2.6g/day) for 28 days, then both for 7 days. Plasma was collected at baseline and at 5 subsequent visits including 4h after each aspirin ingestion. Mixed model methods were used to determine HDL-C-concentrations and apoA-I exchange compared to the baseline visit values. LOWESS curves were used for non-linear analyses of outcomes to help discern change patterns, which was followed by piecewise linear functions for formal testing of curvilinear relationships. RESULTS: Significant changes (p < 0.05) compared to baseline in both HDL-C-concentrations and apoA-I exchange were present at different times. After 7 days of aspirin-only ingestion, apoA-I exchange was significantly modified by increasing levels of DHA concentration, with increased apoA-I exchange observed up until log(DHA) of 4.6 and decreased exchange thereafter (p = 0.03). These LOWESS curve effects were not observed for EPA or HDL-C (p > 0.05). Aspirin's effects on apoA-I exchange were the greatest when EPA or DHA concentrations were moderate compared to high or low. Comparison of EPA, DHA, and EPA+DHA LOWESS curves, demonstrated that the majority of the effect is due to DHA. CONCLUSION: Our results strongly suggest that plasma concentrations of EPA and DHA influence aspirin effects on lipid mediators of CVD event risk where their concentrations are most beneficial when moderate, not high or low. These effects on HDL-C cholesterol and apoA-I exchange are novel. Personalized dosing of DHA in those who take aspirin may be a beneficial option for patients with type 2 diabetes mellitus.
Authors: Robert C Block; Amir Abdolahi; Xin Tu; Steve N Georas; J Thomas Brenna; Richard P Phipps; Peter Lawrence; Shaker A Mousa Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2014-12-22 Impact factor: 4.006
Authors: Sigrun Halvorsen; Felicita Andreotti; Jurriën M ten Berg; Marco Cattaneo; Sergio Coccheri; Roberto Marchioli; João Morais; Freek W A Verheugt; Raffaele De Caterina Journal: J Am Coll Cardiol Date: 2014-07-22 Impact factor: 24.094
Authors: Robert C Block; Amir Abdolahi; Brian Smith; N Meednu; Kelly Thevenet-Morrison; Xueya Cai; Huadong Cui; Shaker Mousa; J Thomas Brenna; S Georas Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2013-05-07 Impact factor: 4.006
Authors: Stefanos G Foussas; Michael N Zairis; Vasilios G Tsirimpis; Stamatis S Makrygiannis; Nikolaos G Patsourakos; Evdokia N Adamopoulou; Demetrios Z Mytas; Athanasios A Prekates; Anna J Perdiou; Vasilios K Tsoukanas; Spyros K Argyrakis Journal: Clin Cardiol Date: 2009-03 Impact factor: 2.882
Authors: Mark S Borja; Lei Zhao; Bradley Hammerson; Chongren Tang; Richard Yang; Nancy Carson; Gayani Fernando; Xiaoqin Liu; Madhu S Budamagunta; Jacques Genest; Gregory C Shearer; Franck Duclos; Michael N Oda Journal: PLoS One Date: 2013-08-28 Impact factor: 3.240
Authors: Robert C Block; Gregory C Shearer; Ashley Holub; Xin M Tu; Shaker Mousa; J Thomas Brenna; William S Harris; Nathan Tintle Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2021-04-24 Impact factor: 3.015
Authors: Faheem W Guirgis; Lauren Page Black; Elizabeth DeVos; Morgan Henson; Jason Ferreira; Taylor Miller; Martin Rosenthal; Christiaan Leeuwenburgh; Colleen Kalynych; Lyle Moldawer; Lisa Jones; Marie Crandall; Srinivasa T Reddy; Hanzhi Gao; Sam Wu; Frederick Moore Journal: J Am Coll Emerg Physicians Open Date: 2020-11-18